Neurologix gene therapy proves effective in Parkinson’s
Neurologix’s 12-patient, dose-escalating phase I trial is the world’s first study to use a viral vector (the non-pathogenic adeno-associated virus, or AAV) for the treatment of an adult
Japan-based Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discovery in neurological diseases.